These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38543169)

  • 1. Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections-In Vitro Susceptibility Testing.
    Brauncajs M; Bielec F; Malinowska M; Pastuszak-Lewandoska D
    Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Bernabeu S; Dortet L
    Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
    Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
    Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
    Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.
    Biagi M; Wu T; Lee M; Patel S; Butler D; Wenzler E
    Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31570403
    [No Abstract]   [Full Text] [Related]  

  • 7. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
    Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E
    Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
    Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
    Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
    Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Santerre Henriksen A; Arena F; Attwood M; Canton R; Gatermann S; Naas T; Morrissey I; Longshaw C;
    Microbiol Spectr; 2024 Jun; 12(8):e0418123. PubMed ID: 38904361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.
    Biagi M; Lamm D; Meyer K; Vialichka A; Jurkovic M; Patel S; Mendes RE; Bulman ZP; Wenzler E
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales.
    Biagi M; Lee M; Wu T; Shajee A; Patel S; Deshpande LM; Mendes RE; Wenzler E
    Diagn Microbiol Infect Dis; 2022 Jun; 103(2):115674. PubMed ID: 35398608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
    Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
    Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of
    Le Terrier C; Nordmann P; Buchs C; Poirel L
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0154823. PubMed ID: 38415988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.
    Nordmann P; Bouvier M; Poirel L
    Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1145-1152. PubMed ID: 37566365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    Lee SY; Gill CM; Nicolau DP;
    J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
    Wilhelm CM; Antochevis LC; Magagnin CM; Arns B; Vieceli T; Pereira DC; Lutz L; de Souza ÂC; Dos Santos JN; Guerra RR; Medeiros GS; Santoro L; Falci DR; Rigatto MH; Barth AL; Martins AF; Zavascki AP
    J Glob Antimicrob Resist; 2024 Sep; 38():247-251. PubMed ID: 38936472
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
    Sader HS; Mendes RE; Carvalhaes CG; Kimbrough JH; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad046. PubMed ID: 36846612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.